Status:
COMPLETED
A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701
Lead Sponsor:
GlaxoSmithKline
Conditions:
HIV Infection
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective observational study which follows on from CNA106030 (a study evaluating whether prospective genetic screening for HLA-B\*5701 can reduce the incidence of hypersensitivity react...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects who have received notification not to receive abacavir in the CNA106030 study because of a positive HLA-B\*5701 screen result, and were subsequently withdrawn from protocol CNA106030.
- Subjects willing and able to understand and provide written informed consent prior to participation in this study.
- French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
- Exclusion criteria:
- Subjects who were not enrolled in the CNA106030 study
- Subjects who are not HLA-B\*5701 positive
- Subjects who do not consent to being told their HLA-B\*5701 status
Exclusion
Key Trial Info
Start Date :
March 1 2007
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00435838
Start Date
March 1 2007
Last Update
October 15 2008
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Graz, Austria, A-8020
2
GSK Investigational Site
Innsbruck, Austria, A-6020
3
GSK Investigational Site
Salzburg, Austria, A-5020
4
GSK Investigational Site
Vienna, Austria, A-1090